APH:LSE-Alliance Pharma plc (GBX)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | LSE

Last Closing Price

GBX 60.90

Change

0.00 (0.00)%

Market Cap

GBX 0.33B

Volume

3.20M

Avg Analyst Target

GBX 145.00 (+138.10%)

Avg User Target

GBX
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

APH Stock Forecast & Price:
Based on the Alliance Pharma plc stock forecasts from 1 analysts, the average analyst target price for Alliance Pharma plc is GBX 145.00 over the next 12 months. Alliance Pharma plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Alliance Pharma plc is Neutral, which is based on 8 positive signals and 7 negative signals. At the last closing, Alliance Pharma plc’s stock price was GBX 60.90. Alliance Pharma plc’s stock price has changed by -17.92% over the past week, -35.89% over the past month and -42.00% over the last year.

About Alliance Pharma plc (APH:LSE)

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approxim ...Read More

Company Website : https://www.alliancepharmaceuticals.com

Address : Avonbridge House, Chippenham, United Kingdom, SN15 2BB

Employees : 250

Fiscal Year End : December

Currency: GBX

Country : UK

Technical Indicators

Beta : 0.46

52 Week High : 120.80

52 Week Low : 58.40

200 Day Moving Average : 104.96

50 Day Moving Average : 88.39

Shares Held By Insiders : 14.23%

Shares Held by Institutions : 80.91%

Dividend Yield : 2.82%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-27 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HLN:LSE Haleon PLC

-7.55 (-2.64%)

 GBX25.55B 17.29 16.25
HIK:LSE Hikma Pharmaceuticals PLC

+31.50 (+2.60%)

 GBX2.66B 9.09 5.27
INDV:LSE Indivior PLC

-0.80 (-0.29%)

 GBX1.92B 14.62 5.99
HCM:LSE HUTCHMED China Ltd

+3.30 (+1.99%)

 GBX1.33B 17.41 -2.31
AMYT:LSE Amryt Pharma plc

N/A

 GBX0.46B N/A 260.86
BXP:LSE Beximco Pharmaceuticals Limite..

N/A

 GBX0.32B 6.50 0.09
BMK:LSE Benchmark Holdings Plc

-1.30 (-3.17%)

 GBX0.29B N/A 12.56
ANCR:LSE Animalcare Group Plc

-15.00 (-5.41%)

 GBX0.16B 3,350.00 17.57
AGY:LSE Allergy Therapeutics

N/A

 GBX0.12B 53.13 306.41
ZOE:LSE Zoetic International Plc

N/A

 GBX0.08B N/A 64.52

ETFs Containing APH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -44.03% 50% F 16% F
Dividend Return 0.01% 67% D+ 21% F
Total Return -44.02% 50% F 16% F
Trailing 12 Months  
Capital Gain -40.76% 69% D+ 21% F
Dividend Return 0.02% 50% F 25% F
Total Return -40.74% 69% D+ 21% F
Trailing 5 Years  
Capital Gain 11.23% 86% B 61% D-
Dividend Return 7.11% 83% B 45% F
Total Return 18.35% 86% B 63% D
Average Annual (5 Year Horizon)  
Capital Gain 10.52% 50% F 76% C
Dividend Return 1.14% 50% F 51% F
Total Return 11.65% 50% F 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 19.35% 100% A+ 43% F
Risk Adjusted Return 60.23% 100% A+ 89% B+
Market Capitalization 0.33B 78% C+ 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 30.45 33% F 15% F
Price/Book Ratio 1.11 67% D+ 50% F
Price / Cash Flow Ratio 8.50 33% F 36% F
EV/EBITDA 11.38 33% F 23% F
Management Effectiveness  
Return on Equity 4.22% 81% B- 34% F
Return on Invested Capital 4.13% 67% D+ 70% C-
Return on Assets 4.26% 81% B- 61% D-
Debt to Equity Ratio 41.09% 22% F 42% F
Technical Ratios  
Dividend Yield 2.82% 60% D- 59% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.46 69% D+ 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector